Pharmaceutical

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval

TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.

May 19, 2024 - 04:00
TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval
TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.
Read the original article

Tags:

Previous Article

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of ...

Next Article

IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bionomics to advance non-SSRI PTSD candidate to Phase III

Bionomics to advance non-SSRI PTSD candidate to Phase III

Mar 22, 2024

Inhibikase’s risvodetinib wins FDA orphan drug designation

Inhibikase’s risvodetinib wins FDA orphan drug designation

Oct 5, 2023

Sotigalimab by Pyxis Oncology for Glioma: Likelihood of...

Oct 27, 2023